AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Patients & Family

Font Size:

The AlloMap Testing Process

Patient Service Centers

Health Insurance

Financial Assistance Program

Terms To Know

FAQ

Financial Assistance Program

The XDx Financial Assistance Program (FAP) provides the following help to patients who are receiving AlloMap testing:

	"Benefit appeals" support to assist the patient in gaining the maximum coverage possible from his or her insurer and minimizing the patient’s out-of-pocket expense, and
	Financial assistance for patients who qualify based on a comparison of their income and/or other financial resources to the Federal Poverty Guidelines

Patients can contact XDx Patient Financial Services to:

	Find out how they may apply for assistance
	Discuss any information they may have received from their insurer about this test
	Ask questions about the coverage of the test

Call 1-888-ALLOMAP to ask a representative about the XDx financial assistance program for under-insured and uninsured patients.